The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis (original) (raw)

ASHP Therapeutic Position Statement on the Use of Antipsychotic Medications in the Treatment of Adults with Schizophrenia and Schizoaffective Disorder

Jason Noel

American Journal of Health-system Pharmacy, 2020

View PDFchevron_right

Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia

Jari Tiihonen

JAMA Psychiatry, 2019

View PDFchevron_right

Effectiveness of clozapine in treatment-resistant schizophrenia

Raguraman Janakiraman

Indian Journal of Psychiatry, 2005

View PDFchevron_right

The Effect of Antipsychotics on Cognition in Schizophrenia—A Current Narrative Review

Fabian Lungu

Brain sciences, 2024

View PDFchevron_right

Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

George Garibaldi

Schizophrenia Research, 2013

View PDFchevron_right

Increased use of second generation antipsychotic drugs in primary care: potential relevance for hospitalizations in schizophrenia patients

Eva Peñas Lledó

European Journal of Clinical Pharmacology, 2007

View PDFchevron_right

When Symptoms Persist: Choosing Among Alternative Somatic Treatments for Schizophrenia

George Christison

Schizophrenia Bulletin, 1991

View PDFchevron_right

Efficacy and Safety of Pharmacological and Psychological Interventions for the Treatment of Psychosis and Schizophrenia in Children, Adolescents and Young Adults: A Systematic Review and Meta-Analysis

Chris Hollis

PLOS ONE, 2015

View PDFchevron_right

Clinical Characteristics of Patients With Schizophrenia Who Successfully Discontinued Antipsychotics

Takefumi Suzuki

Journal of Clinical Psychopharmacology, 2018

View PDFchevron_right

Influencing factors and predictors of early improvement in the acute treatment of schizophrenia and schizophrenia spectrum disorder

Eckart Ruether

Journal of Psychiatric Research, 2011

View PDFchevron_right

Delay to first antipsychotic medication in schizophrenia: impact on symptomatology and clinical course of illness

Gretchen Haas

Journal of Psychiatric Research, 1998

View PDFchevron_right

Efficacy and safety of clozapine combination with different antipsychotics in schizophrenia: a systematic review

Zullies Ikawati

Indonesian Journal of Pharmacology and Therapy, 2024

View PDFchevron_right

Long-Acting Risperidone and Oral Antipsychotics in Schizophrenia

Robert Rosenheck

New England Journal of Medicine, 2011

View PDFchevron_right

Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia

S. Kleisas

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010

View PDFchevron_right

Cognitive Effects of Antipsychotic Drugs in First-Episode Schizophrenia and Schizophreniform Disorder: A Randomized, Open-Label Clinical Trial (EUFEST)

Michael Davidson

American Journal of Psychiatry, 2009

View PDFchevron_right

A meta-analysis of effectiveness of real-world studies of antipsychotics in schizophrenia: Are the results consistent with the findings of randomized controlled trials?

István Bitter

Translational Psychiatry

View PDFchevron_right

Infectious agents associated with schizophrenia: A meta-analysis

Jorge Cervilla

Schizophrenia Research, 2012

View PDFchevron_right

Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial

James Gold

Archives of General Psychiatry, 2007

View PDFchevron_right

Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses

B. Mutamba

Health Economics Review, 2012

View PDFchevron_right

Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study

Richard Laugharne

Acta Psychiatrica Scandinavica, 2006

View PDFchevron_right

Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study

Robert Rosenheck

Schizophrenia Research, 2008

View PDFchevron_right

Inconclusive Evidence for the Efficacy of Olanzapine in the Treatment of Negative Symptoms in Schizophrenia

Brendan Murphy

The Journal of Clinical Psychiatry, 2008

View PDFchevron_right

A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia

mohammad reza khodaie

Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2008

View PDFchevron_right

Clinical Course, Neurobiology and Therapeutic Approaches to Treatment Resistant Schizophrenia. Toward an Integrated View

Arsime Demjaha

Frontiers in Psychiatry, 2019

View PDFchevron_right

Multidimensional Assessment of Functional Outcomes in Schizophrenia: Results From QUALIFY, a Head-to-Head Trial of Aripiprazole Once-Monthly and Paliperidone Palmitate

Karina Hansen

International Journal of Neuropsychopharmacology, 2016

View PDFchevron_right